The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation

被引:0
|
作者
Rossi, Esther Diana [1 ]
Bizzarro, Tommaso [1 ]
Granja, Sara [2 ,3 ]
Martini, Maurizio [1 ]
Capodimonti, Sara [1 ]
Luca, Emilia [1 ]
Fadda, Guido [1 ]
Lombardi, Celestino Pio [4 ]
Pontecorvi, Alfredo [5 ]
Larocca, Luigi Maria [1 ]
Baltazar, Fatima [2 ,3 ]
Schmitt, Fernando [6 ,7 ,8 ]
机构
[1] Catholic Univ Sacred Heart Rome, Div Anat Pathol, Milan, Italy
[2] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal
[3] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
[4] Univ Cattolica Sacro Cuore, Div Endocrine Surg, Milan, Italy
[5] Univ Cattolica Sacro Cuore, Div Endocrinol, Milan, Italy
[6] Med Fac Univ, Porto, Portugal
[7] Inst Pathol Mol Immunol Porto, Porto, Portugal
[8] Lab Natl Sante Luxembourg, Luxembourg, Luxembourg
关键词
Liquid-based cytology; Thyroid lesions; PTC; Plump cells; MCTs; BRAF(V600E) mutation; LIQUID-BASED CYTOLOGY; ASPIRATION BIOPSIES; MALIGNANT-MELANOMA; PROGNOSTIC VALUE; BRAF(V600E); CANCER; CELLS; IMMUNOHISTOCHEMISTRY; IMPACT; CD147;
D O I
10.1007/s12020-016-1044-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BRAF (V600E) mutation, usually performed by DNA techniques, is one of the most common diagnostic markers in papillary thyroid carcinoma. Few papers have demonstrated that plump cells (eosinophilic cytoplasms and papillary thyroid carcinoma nuclei) and peculiar sickle-shaped nuclei represent morphological features of BRAF (V600E) on papillary thyroid carcinomas. These features seem to be linked to glycolytic phenotype whereby monocarboxylate transporters 1-4 are hypothesized to have a dominant role as lactate transporters. We investigated the association between these morphological features and monocarboxylate transporters 1 and 4 in 48 cyto-histological samples diagnosed as "positive for malignancy-favoring papillary thyroid carcinoma". These cases were processed with liquid-based cytology and underwent BRAF (V600E) mutational analysis (pyrosequencing) on liquid-based cytology and monocarboxylate transporters immunostaining on histology. The expression of monocarboxylate transporter 1, monocarboxylate transporter 4, glucose trasporter-1 and carbonic anhidrase were scored semi-quantitatively with expression from 0 to 3+ (strong positivity). The 33 mutated and 15 wild type cases showed 100 % cyto-histological concordance. The cytological evaluation revealed plump cells and sickle nuclear shape in 100 % mutated cases. Monocarboxylate transporter 1 yielded 76 % positivity in the mutated cases especially in both the plump cells and sickle-shaped nuclei, whereas the wild types showed 13.3 % positive monocarboxylate transporter 1 (p = 0.00013). Monocarboxylate transporter 4 resulted in 100 % positivity in mutated and 40 % in wild types (p < 0.005). Furthermore, 20 % of the wild types showed weak monocarboxylate transporter 1 nuclear expression associated to a less aggressive behavior. The analysis of glucose trasporter-1 and carbonic anhidrase did not highlight any statistical significance (p > 0.05). This is the first report analyzing the association between monocarboxylate transporter expression and the morphological features of BRAF (V600E) mutated papillary thyroid carcinomas suggesting the possible involvement of lactate in the morphological features.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 50 条
  • [1] The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAFV600E mutation
    Esther Diana Rossi
    Tommaso Bizzarro
    Sara Granja
    Maurizio Martini
    Sara Capodimonti
    Emilia Luca
    Guido Fadda
    Celestino Pio Lombardi
    Alfredo Pontecorvi
    Luigi Maria Larocca
    Fatima Baltazar
    Fernando Schmitt
    Endocrine, 2017, 56 : 379 - 387
  • [2] BRAF V600E Mutation in Anaplastic Thyroid Carcinoma
    Walts, A. E.
    Pao, A.
    Bose, S.
    LABORATORY INVESTIGATION, 2014, 94 : 161A - 161A
  • [3] BRAF V600E Mutation in Anaplastic Thyroid Carcinoma
    Walts, A. E.
    Pao, A.
    Bose, S.
    MODERN PATHOLOGY, 2014, 27 : 161A - 161A
  • [4] BRAF V600E mutation status in anaplastic thyroid carcinoma
    Nonaka, D.
    Rushton, S.
    Burghel, G.
    Wallace, A.
    VIRCHOWS ARCHIV, 2015, 467 : S71 - S71
  • [5] BRAF V600E Mutation Status in Anaplastic Thyroid Carcinoma
    Nonaka, Daisuke
    Rushton, Sarah
    Burghel, George
    Wallace, Andrew
    MODERN PATHOLOGY, 2015, 28 : 139A - 139A
  • [6] BRAF V600E Mutation Status in Anaplastic Thyroid Carcinoma
    Nonaka, Daisilke
    Rushton, Sarah
    Burghel, George
    Wallace, Andrew
    LABORATORY INVESTIGATION, 2015, 95 : 139A - 139A
  • [7] Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
    Li, Qian
    Yuan, Jianjun
    Wang, Yan
    Zhai, Yuanpeng
    ONCOLOGY LETTERS, 2017, 14 (02) : 1439 - 1444
  • [8] Nuclear pseudoinclusion is associated with BRAF V600E mutation: Analysis of nuclear features in papillary thyroid carcinoma
    Harahap, Agnes Stephanie
    Khoirunnisa, Dina
    Salinah
    Ham, Maria Francisca
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2025, 75
  • [9] Immunohistochemical expression of BRAF V600E mutation in thyroid lesions
    Kyrodimou, E.
    Koutsonikas, G.
    Kostopoulou, A.
    Minaidou, E.
    Papanastasiou, L.
    Theodosiou, D.
    Choreftaki, T.
    VIRCHOWS ARCHIV, 2014, 465 : S213 - S213
  • [10] BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas
    da Silva, R. C.
    de Paula, H. S. C.
    Leal, C. B. Q. S.
    Cunha, B. C. R.
    de Paula, E. C.
    Alencar, R. C. G.
    Meneghini, A. J.
    Silva, A. M. T. C.
    Gontijo, A. P.
    Wastowski, I. J.
    Saddi, V. A.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (02) : 5065 - 5075